Metabolism-Based Liquid Biopsy Tool Being Developed by Elypta for Recurrent Renal Cell Cancer

Feb 06, 2019

|

Premium

NEW YORK (360Dx) – Chalmers University of Technology spinout Elypta is developing a metabolism-based liquid biopsy platform for detection and monitoring of cancers, including early detection of recurrent renal cell carcinoma (RCC) after surgery.

Elypta is advancing research, that originated at Chalmers in Gothenburg, Sweden, into the use of glycosaminoglycan metabolites as diagnostic biomarkers for a range of cancer diagnostic applications, the firm's CEO Karl Bergman said in an interview.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Menu